How Much Does Ozempic Cost in Virginia in 2026?

Virginia Retail Pricing for Ozempic

The average cash-pay price for Ozempic at Virginia retail pharmacies in 2026 sits at $998 per month, matching Novo Nordisk's wholesale acquisition cost. This figure applies across all four pen strengths (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg) because each carton contains a single prefilled pen delivering four weekly doses [1].

Pricing varies only modestly between Virginia pharmacy chains. CVS, Walgreens, and independent pharmacies in the Richmond, Virginia Beach, and Northern Virginia metro areas typically quote within $20 of the $998 benchmark. Costco and Amazon Pharmacy occasionally list prices $30 to $60 below list, though availability fluctuates with supply allocation.

The FDA first approved semaglutide injection (Ozempic) in December 2017 as an adjunct to diet and exercise for adults with type 2 diabetes [2]. Since then, the list price has increased from $850 to $998 per month. That 17.4% increase over roughly eight years outpaces general medical inflation but remains typical for branded GLP-1 receptor agonists. SUSTAIN-7 (N=1,201) demonstrated that semaglutide 0.5 mg and 1.0 mg produced HbA1c reductions of 1.5% and 1.8%, respectively, versus dulaglutide at 48 weeks, establishing the clinical value underpinning this pricing [3].

For uninsured patients in Virginia, $998 per month translates to $11,976 annually. That figure exceeds 10% of median household income in several Virginia counties, including those in the southwestern Appalachian region where type 2 diabetes prevalence runs highest.

Insurance Coverage Across Virginia Plans

Most major commercial insurers operating in Virginia include Ozempic on their formularies, though tier placement and prior authorization requirements differ substantially between plans.

Anthem Blue Cross Blue Shield Virginia, the state's largest commercial carrier, covers Ozempic on its preferred brand tier (Tier 3) with a required prior authorization confirming a type 2 diabetes diagnosis and documented trial of metformin [4]. Copays range from $35 to $100 depending on the specific plan. Optima Health, which covers much of the Hampton Roads and central Virginia corridor, places Ozempic on Tier 2 for many employer-sponsored plans, resulting in copays as low as $25.

UnitedHealthcare and Aetna plans sold through the Virginia Health Benefit Exchange (via HealthCare.gov) generally require step therapy. The standard pathway demands a 90-day trial of metformin plus documentation of HbA1c remaining above 7.0% before authorizing Ozempic [5]. Once authorized, monthly copays on marketplace silver plans typically fall between $75 and $150.

TRICARE, which covers a significant population in Virginia given the concentration of military installations around Norfolk, Hampton Roads, and the Pentagon corridor, lists Ozempic on its formulary with Tier 3 preferred status. TRICARE beneficiaries filling at military pharmacies pay $0; those using retail pharmacies pay $28 for a 30-day supply [6].

"Prior authorization for GLP-1 receptor agonists should not be a barrier to evidence-based diabetes care. The clinical data supporting semaglutide's glycemic and cardiovascular benefits are strong enough to warrant streamlined access," stated the American Association of Clinical Endocrinology (AACE) in its 2024 consensus statement on GLP-1 RA access [7].

Virginia Medicaid and Ozempic

Virginia Medicaid covers Ozempic with prior authorization specifically for type 2 diabetes management. The Virginia Department of Medical Assistance Services (DMAS) requires prescribers to document that the patient has a confirmed diagnosis of type 2 diabetes, an HbA1c of 7.0% or above, and has either tried or has a contraindication to metformin [8].

Virginia expanded Medicaid in January 2019, adding approximately 500,000 adults to the rolls. As of early 2026, Virginia Medicaid covers over 2.1 million residents. For these beneficiaries, Ozempic copays are capped at $1 to $3 per prescription under federal Medicaid cost-sharing limits.

Off-label use for weight management alone is not covered under Virginia Medicaid's current preferred drug list. Patients seeking GLP-1 therapy specifically for obesity through Medicaid would need a prescription for Wegovy (semaglutide 2.4 mg), which Virginia Medicaid also covers with prior authorization and a BMI threshold of 30 kg/m² (or 27 kg/m² with at least one weight-related comorbidity).

Processing times for Ozempic prior authorization through Virginia Medicaid average 3 to 5 business days when submitted electronically via the state's CoverMyMeds portal. Denials can be appealed through the DMAS fair hearing process within 30 days.

Compounded Semaglutide in Virginia

Compounded semaglutide is available in Virginia through licensed 503A compounding pharmacies at an average cash price of roughly $199 per month. This represents an 80% savings compared to brand-name Ozempic.

503A pharmacies compound medications pursuant to individual patient prescriptions under Virginia Board of Pharmacy oversight. Virginia state law permits 503A compounding when a prescriber determines that a commercially available product does not meet the specific medical needs of a patient, such as when a different concentration, dosing interval, or delivery vehicle is required [9].

The FDA's position on compounded semaglutide has shifted over time. In early 2024, the FDA removed semaglutide from the drug shortage list, which narrowed the legal basis for compounding under federal 503B outsourcing facility rules. However, 503A patient-specific compounding in Virginia operates under a different legal framework and remains permissible when prescribed for an individual patient by a licensed provider [10].

Key distinctions between compounded and brand-name semaglutide matter clinically. Compounded versions may use semaglutide base rather than semaglutide sodium, potentially affecting bioavailability. Compounded products do not undergo FDA review for safety, efficacy, or manufacturing consistency. The Endocrine Society's 2024 position statement noted: "Patients receiving compounded semaglutide should be informed that these products have not been evaluated in clinical trials and may differ in potency, sterility, and stability from FDA-approved formulations" [11].

Virginia patients considering compounded semaglutide should verify that their pharmacy holds a valid Virginia Board of Pharmacy compounding license and follows USP 797 sterile compounding standards. A list of licensed pharmacies is searchable through the Virginia Board of Pharmacy's online verification portal.

Novo Nordisk Savings Card and Discount Programs

The Novo Nordisk Ozempic Savings Card reduces out-of-pocket costs for commercially insured Virginia patients to as low as $25 per 30-day fill, with a maximum annual benefit of $150 per fill for up to 24 months [12].

Eligibility requirements exclude patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government insurance program. The card also cannot be used if the patient's commercial plan excludes Ozempic from its formulary entirely. Patients activate the card through the Ozempic manufacturer website or by calling 1-877-304-6855.

Beyond the manufacturer card, several other discount pathways exist for Virginia residents:

GoodRx and RxSaver coupons bring the cash price at select Virginia pharmacies to $890 to $940, a modest but meaningful reduction from the $998 list price. These coupons cannot be combined with insurance.

Novo Nordisk's Patient Assistance Program (PAP) provides Ozempic at no cost for uninsured patients with household incomes below 400% of the federal poverty level ($62,400 for a single individual in 2026). Virginia patients apply through the NovoCare website with income verification documentation [13].

The Virginia Rx Card, a state-affiliated discount program, offers 10% to 15% discounts on GLP-1 medications at participating pharmacies, though actual savings on Ozempic are typically smaller than manufacturer-direct programs.

Telehealth Prescribing in Virginia

Ozempic can be legally prescribed via telehealth in Virginia. The Virginia Board of Medicine permits telehealth prescribing of scheduled and non-scheduled prescription medications, including GLP-1 receptor agonists, provided a valid provider-patient relationship is established through synchronous audio-visual encounter [14].

Virginia's telehealth parity law (Va. Code § 38.2-3418.16) requires commercial insurers to reimburse telehealth visits at the same rate as in-person encounters, meaning Virginia patients do not face a financial penalty for obtaining an Ozempic prescription remotely.

Multiple telehealth platforms serve Virginia patients for GLP-1 prescribing. HealthRX, Ro, Calibrate, and Found all operate in Virginia with providers licensed by the Virginia Board of Medicine. Initial consultations typically cost $99 to $199, with follow-up visits ranging from $49 to $99 per month.

For patients in rural western Virginia, where endocrinology access can require 60 to 90-mile drives to the nearest specialist, telehealth prescribing has become a particularly important access pathway. The Virginia Telehealth Network reported a 340% increase in metabolic health telehealth visits between 2022 and 2025 [15].

How Virginia Costs Compare to Neighboring States

Ozempic's list price is identical across all U.S. states at $998 per month, but effective out-of-pocket costs vary based on state Medicaid policies, insurance market composition, and compounding pharmacy availability.

Virginia's Medicaid prior authorization pathway mirrors those in Maryland and North Carolina. West Virginia Medicaid, by contrast, restricts GLP-1 coverage more tightly, requiring documentation of failed dual oral therapy before authorizing injectable agents. Washington, D.C. Medicaid covers Ozempic with a simpler single-step prior authorization.

Compounded semaglutide pricing in Virginia ($199 per month average) aligns closely with North Carolina and Tennessee. Maryland compounding pharmacies tend to charge $220 to $250 per month due to higher operating costs in the Baltimore-Washington corridor.

The concentration of federal employees in Northern Virginia creates a distinct insurance dynamic. Federal Employees Health Benefits (FEHB) plans, which cover approximately 400,000 Virginia residents, generally provide Tier 2 or Tier 3 coverage for Ozempic with copays of $30 to $75 after a formulary-specific prior authorization [16].

Strategies for Reducing Your Ozempic Cost in Virginia

Start with your insurance formulary. Call the number on the back of your insurance card and ask specifically whether Ozempic carries preferred status, what the copay tier is, and whether prior authorization is needed. Request that your prescriber submit the PA before your first fill to avoid delays.

If your copay exceeds $25, apply for the Novo Nordisk Savings Card immediately. This single step eliminates the cost gap between Tier 2 and Tier 3 placement for most commercially insured patients.

Uninsured patients earning below 400% FPL should apply for the Novo Nordisk Patient Assistance Program before considering cash-pay options. Approval typically takes 2 to 4 weeks and provides Ozempic at zero cost.

For patients who remain uninsured and above the PAP income threshold, compounded semaglutide from a Virginia-licensed 503A pharmacy at $199 per month represents the most significant cost reduction available. Discuss this option with your prescriber, who can evaluate whether a compounded formulation is clinically appropriate for your situation.

The SUSTAIN trial program, spanning SUSTAIN-1 through SUSTAIN-10, enrolled over 10,000 patients and demonstrated consistent HbA1c reductions of 1.2% to 1.8% across diverse populations, reinforcing semaglutide's position as a first-line injectable option worth pursuing through available access pathways [3][17].

Fill 90-day supplies when your plan allows. Most Virginia commercial plans and TRICARE offer 90-day mail-order fills at two-times the 30-day copay, saving one copay per quarter.